Mizuho Maintains Outperform on Chemours, Lowers Price Target to $25
Mizuho analyst John Roberts maintains Chemours (NYSE: CC ) with a Outperform and lowers the price target from $30 to $25.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.